RxDoctor Payments Data

Kafi Rudolph, DO

Family Medicine · Cherry Hill, NJNPI 1023499340

Payments from drug & device makers

$768in general payments, 2019–2025

Across 31 payments — averaging $24.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$220
  • AstraZeneca$125
  • Exact Sciences$112
  • Kowa Pharmaceuticals America, Inc.$98
  • Amgen$55
  • Currax Pharmaceuticals LLC$54
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$768100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$768 in reported general payments places this provider in the 60th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$29,320
Medicare patients
170
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$41,371
JardianceEmpagliflozin29$35,427
OzempicSemaglutide19$26,881
FarxigaDapagliflozin Propanediol27$26,221
JanuviaSitagliptin Phosphate13$21,483
TrulicityDulaglutide13$15,659
Breo ElliptaFluticasone/Vilanterol21$11,277
Atorvastatin Calcium495$5,754
Incruse ElliptaUmeclidinium Bromide16$5,649
Albuterol Sulfate HfaAlbuterol Sulfate120$4,161
Rosuvastatin Calcium126$2,474
Amlodipine Besylate291$1,884
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,860
Metoprolol Succinate102$1,790
Levothyroxine Sodium175$1,773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$220$26,88119 claims
AstraZenecaFarxiga$125$26,22127 claims
GSKBreo Ellipta, Incruse Ellipta$12$16,92637 claims
AbbVieSynthroid$14$1,16016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →